Benign Prostatic Hyperplasia Treatment Market Set to Record Exponential Growth

Benign Prostatic Hyperplasia Treatment Market Outlook 2031

The global benign prostatic hyperplasia treatment market was valued at US$ 6.9 Bn in 2021

The global market is projected to grow at a CAGR of 5.5% from 2022 to 2031

The global benign prostatic hyperplasia treatment market is anticipated to reach more than US$ 11.9 Bn by the end of 2031

Read Report Overview: https://www.transparencymarketresearch.com/benign-prostatic-hyperplasia-treatment-market.html

Benign Prostatic Hyperplasia Treatment Market Introduction

The prostate is a walnut-sized gland situated just below the bladder and adjacent to the urethra as part of the male reproductive system. The prostate gland, which consists of four lobes (anterior, posterior, lateral, and medial), generates a fluid that combines with seminal vesicle secretions to generate most of the seminal fluid volume.

Benign prostatic hyperplasia (BPH) is a progressive disorder, wherein the prostate expands as part of the aging process or as a result of a disease. Incidence of benign prostatic hyperplasia increases significantly with age. Prostate development between puberty and the middle age is generally negligible. The exact cause of BPH is unknown, but the disease most frequently occurs in elderly males. It is probably caused due to hormonal changes. Several theories suggest that greater estrogen or dihydrotestosterone concentrations lead to hyperplastic development, although none are conclusive. The function of testosterone in BPH growth is still uncertain.

Currently, benign prostatic hyperplasia is one of the most common benign tumors observed in men across the globe. Benign prostatic hyperplasia is more prevalent in men aged 40 years and above. A study by the National Center for Biotechnology Information (NCBI) stated that the risk of benign prostatic hyperplasia is less common among the population of Asia than in the Caucasian population in the West. Around 50% of men below the age of 60 who underwent surgery for benign prostatic hyperplasia had a heritable form of the disease.

With progressively aging population and changing population profile in nearly all societies, benign prostatic hyperplasia is expected to become a major challenge for all health care systems. It is anticipated to become even more prevalent in men during the forecast period.

Request a Sample: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=72273

Increase in Geriatric Population to Drive Demand for Benign Prostatic Hyperplasia Treatment

As per the benign prostatic hyperplasia treatment market analysis, increase in geriatric population is a major driver of the global market. Elderly individuals increase the patient pool in major regions of the world. According to the World Health Organization (WHO), the global geriatric population is likely to reach 2 billion (22% of the global population) by 2050 as against 962 million in 2017. The global geriatric population is expected to increase at the fastest rate in developed countries such as the U.S., the U.K., and Japan. Brazil, China, Thailand, and South Korea are likely to have a large geriatric population in the shortest span of time in the near future.

Surge in geriatric population is projected to propel the global benign prostatic hyperplasia treatment market size, as the population is more prone to various age-related as well as chronic diseases. The need for benign prostatic hyperplasia treatment among such patients is relatively higher. This is anticipated to drive the global benign prostatic hyperplasia treatment market.

Request For Custom Research: https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=72273

Rise in Adoption of Minimally Invasive Surgeries to Propel Benign Global Prostatic Hyperplasia Treatment Market

Established types of minimally invasive surgery include electrocautery-based TURP, transurethral incision of the prostate (TUIP), and transurethral vaporization of the prostate (TUVP), although the latter technique is used infrequently. TURP is the most popular minimally invasive surgical procedure for relieving severe medical BPH symptoms, while radical prostatectomy based on open surgery is rarely used in the therapy of BPH, almost solely for indications of prostate cancer.

Adoption of minimally invasive surgeries has been increasing significantly due to various advantages such as less post-operative pain, less blood loss, reduced hospital stay, and faster recovery. This is likely to propel the global benign prostatic hyperplasia (BPH) treatment market during the forecast period.

Request Report Methodology: https://www.transparencymarketresearch.com/sample/sample.php?flag=RRM&rep_id=72273

Growth in Geriatric Population to Augment Global Benign Prostatic Hyperplasia Treatment Market

Prostate development is generally negligible between puberty and middle age; however, hormonal modifications could cause the gland to enlarge when a person reaches age 40 (for most males). Studies of autopsy have found the histological incidence of BPH. Thus, increase in geriatric population that is prone to urological diseases is projected to drive the benign prostatic hyperplasia (BPH) treatment market in the U.S.

Proven High Efficacy to Drive Alpha-blockers Segment

Alpha-blockers block0020alpha-adrenoceptors on the smooth muscle of the prostate, prostatic urethra, and bladder neck, leading to decreased muscle tone and reduction in the bladder obstruction. Alpha-blockers include alfuzosin hydrochloride (Uroxatral), silodosin (Rapaflo), tamsulosin hydrochloride (Flomax), and terazosin (Hytrin). Alpha-blockers are prescribed for men who have moderate to severe BPH symptoms. The proven high efficacy of alpha-blockers is expected to propel the alpha-blockers segment during the forecast period.

Ask References: https://www.transparencymarketresearch.com/sample/sample.php?flag=ARF&rep_id=72273

Most Preferred Approach for Benign Prostatic Hyperplasia Treatment Propelling TURP Segment

Currently, transurethral resection of the prostate (TURP) is the most preferred approach used by surgeons or urologists for benign prostatic hyperplasia treatment. TURP is an endoscopic electrosurgical procedure involving the removal of a portion of the prostate to relieve voiding obstruction associated with BPH. A specialized cystoscope known as a resectoscope is inserted into the urethra and threaded into the bladder. Following the procedure, most patients stay in the hospital between one and four days for observation. However, the trend is to perform TURP on an outpatient basis, and select patients are discharged within 24 hours of admission.

Analysis of Key Players Global Benign Prostatic Hyperplasia Treatment Market

The report also provides profiles of leading players operating in the global benign prostatic hyperplasia treatment market. These include Abbott, Allergan plc, Astellas Pharma, Inc., Asahi Kasei Corporation, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Pfizer, Inc., Sanofi, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Teleflex Incorporated, Endo International plc, Urologix, LLC, LISA Laser Surgeries, and Olympus Corporation.

Enquiry Before Buying: https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=72273

Key Developments in Global Benign Prostatic Hyperplasia Treatment Market

In April 2022, Teleflex announced the launch of the UroLift System in Japan for the treatment of benign prostatic hyperplasia (BPH). The FDA had cleared the usage of UroLift System for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH).

In September 2018, Boston Scientific Corporation acquired Augmenix, the developer of SpaceOAR intended to reduce common and debilitating side effects for men who undergo prostate cancer radiotherapy

In March 2018, Boston Scientific Corporation acquired NxThera, the developer of the Rezūm system, which is a minimally invasive therapy for patients with BPH
In September 2017, Teleflex Incorporated and NeoTract, Inc. entered into a definitive agreement for the acquisition of NeoTract in a transaction valued up to US$ 1.1 Bn. NeoTract is a privately-held medical device company that has developed and commercialized the FDA-cleared UroLift System, a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia.

Each of these players has been profiled in the benign prostatic hyperplasia treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit Bhisey
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: sales@transparencymarketresearch.com

This release was published on openPR.